In this episode, Erika P. Hamilton, MD, and Komal Jhaveri, MD, discuss their approaches to and key studies for current management of patients with HER2-positive breast cancer. The discussion includes: 

• Optimizing systemic therapy for patients with HER2-positive early breast cancer based on disease characteristics and risk
• Sequencing available therapies for patients with HER2-positive metastatic disease, including new data on first- and second-line therapy and how to manage patients with central nervous system metastases
• Managing common adverse events associated with HER2-targeted therapy

Presenters:

Erika P. Hamilton, MD
Director, Breast and Gynecologic Cancer Research Program
Drug Development Unit
Sarah Cannon Research Institute
Investigator
Tennessee Oncology
Nashville, Tennessee

Komal Jhaveri, MD
Assistant Professor of Medicine
Weill Cornell Medical College
Associate Attending Physician
Breast Medicine Service
Department of Medicine
Memorial Sloan Kettering Cancer Center
New York, New York

Follow along with Podcast Pearls slideset:
https://bit.ly/3eMqxB8

See full program:  
https://bit.ly/3oBdd45